Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Immune activation, CD4+ T cell counts, and viremia exhibit oscillatory patterns over time in patients with highly resistant HIV infection.

Kitchen CM, Yeghiazarian L, Hoh R, McCune JM, Sinclair E, Martin JN, Deeks SG.

PLoS One. 2011;6(6):e21190. doi: 10.1371/journal.pone.0021190. Epub 2011 Jun 20.

2.

The independent effect of drug resistance on T cell activation in HIV infection.

Hunt PW, Deeks SG, Bangsberg DR, Moss A, Sinclair E, Liegler T, Bates M, Tsao G, Lampiris H, Hoh R, Martin JN.

AIDS. 2006 Mar 21;20(5):691-9.

PMID:
16514299
3.

Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.

Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG.

AIDS. 2004 Apr 30;18(7):981-9.

PMID:
15096800
4.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

5.

Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy.

Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H.

J Infect Dis. 2005 Feb 1;191(3):348-57. Epub 2004 Dec 30.

PMID:
15633093
6.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.

Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V; Red de Investigación en SIDA.

J Med Virol. 2005 Sep;77(1):23-8.

PMID:
16032728
7.

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

Schapiro JM, Winters MA, Stewart F, Efron B, Norris J, Kozal MJ, Merigan TC.

Ann Intern Med. 1996 Jun 15;124(12):1039-50.

PMID:
8633817
9.

Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.

Al Mazari A, Zomaya AY, Charleston M, Salem H, Maher A, Garsia RJ.

Curr HIV Res. 2007 Jul;5(4):430-9.

PMID:
17627506
10.

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.

Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM.

AIDS. 2008 Aug 20;22(13):1583-8. doi: 10.1097/QAD.0b013e328305bd77.

PMID:
18670217
11.

Correlation between gag-specific CD8 T-cell responses, viral load, and CD4 count in HIV-1 infection is dependent on disease status.

Jiao Y, Xie J, Li T, Han Y, Qiu Z, Zuo L, Wang A.

J Acquir Immune Defic Syndr. 2006 Jul;42(3):263-8.

PMID:
16763520
12.

Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy.

Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG.

J Infect Dis. 2008 Jan 1;197(1):126-33. doi: 10.1086/524143.

14.

T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.

Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG.

J Infect Dis. 2003 May 15;187(10):1534-43. Epub 2003 Apr 23.

PMID:
12721933
15.

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.

Staszewski S, Miller V, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidemann E, Hill A, Phillips A.

AIDS. 1999 May 28;13(8):951-6.

PMID:
10371176
16.

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.

Bisset LR, Cone RW, Huber W, Battegay M, Vernazza PL, Weber R, Grob PJ, Opravil M.

AIDS. 1998 Nov 12;12(16):2115-23.

PMID:
9833852
17.

Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.

Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Chouraqui M, Pisapia M, Delbeke E.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):44-55.

PMID:
11176268
18.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.

Vallejo A, Gutierrez C, Hernandez-Novoa B, Diaz L, Madrid N, Abad-Fernandez M, Dronda F, Perez-Elias MJ, Zamora J, Muñoz E, Muñoz-Fernandez MA, Moreno S.

AIDS. 2012 Sep 24;26(15):1885-94.

PMID:
22992577
19.

Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells.

Stellbrink HJ, van Lunzen J, Hufert FT, Fröschle G, Wolf-Vorbeck G, Zöllner B, Albrecht H, Greten H, Racz P, Tenner-Racz K.

AIDS. 1997 Jul 15;11(9):1103-10.

PMID:
9233456
20.

HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Goujard C, Girault I, Rouzioux C, Lécuroux C, Deveau C, Chaix ML, Jacomet C, Talamali A, Delfraissy JF, Venet A, Meyer L, Sinet M; ANRS CO6 PRIMO Study Group.

Antivir Ther. 2012;17(6):1001-9. doi: 10.3851/IMP2273. Epub 2012 Aug 6.

PMID:
22865544

Supplemental Content

Support Center